SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
ST. LOUIS, Aug. 03, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 second quarter ended June 30, 2017 on Thursday, August 10, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis second quarter 2017 financial results conference call |
| When: | Thursday, August 10th at 10:00 a.m. Eastern Time (7:00 a.m. PT) |
| Dial In Number: | To access the live call, dial 800-946-0706 (US and Canada) or 719-457-2642 (International) and give the participant pass code 1952158. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com |
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Thursday, August 17, 2017. To access the replay dial-in information, please click here. |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts: David L. Fischel Chairman and Acting Chief Executive Officer Martin C. Stammer Chief Financial Officer [email protected]
